Meds & supplements › Natalizumab
Medicine · Integrin Receptor Antagonist
TYSABRI is an integrin receptor antagonist indicated for treatment of
Selected manufacturer label information, organised into consistent sections by Sofidex. Read the full label at DailyMed ↗
WARNING: PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY TYSABRI increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability. Risk factors for the development of PML include the presence of anti-JCV antibodies, duration of therapy, and prior use of immunosuppressants. These factors should be considered in the context of expected benefit when initiating and continuing treatment with TYSABRI. Healthcare professionals should monitor patients on TYSABRI for any new sign or symptom that may be suggestive of PML. TYSABRI dosing should be withheld immediately at the first sign or symptom suggestive of PML. For diagnosis, an evaluation that includes a gadolinium-enhanced magnetic resonance imaging (MRI) scan of the brain and, when indicated, cerebrospinal fluid analysis for JC viral DNA are recommended. Because of the risk of PML, TYSABRI is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the TOUCH ® Prescribing Program. WARNING: PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY See full prescribing information for complete boxed warning TYSABRI increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability Risk factors for the development of PML include the presence of anti-JCV antibodies, duration of therapy, and prior use of immunosuppressants. These factors should be considered in the context of expected benefit when initiating and continuing treatment with TYSABRI Monitor patients, and withhold TYSABRI immediately at the first sign or symptom suggestive of PML Because of the risk of PML, TYSABRI is available only through a restricted distribution program called the TOUCH ® Prescribing Program
TYSABRI is an integrin receptor antagonist indicated for treatment of: Multiple Sclerosis (MS) TYSABRI is indicated as monotherapy for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. TYSABRI increases the risk of PML.
When initiating and continuing treatment with TYSABRI, physicians should consider whether the expected benefit of TYSABRI is sufficient to offset this risk. Crohn's Disease (CD) TYSABRI is indicated for inducing and maintaining clinical response and remission in adult patients with moderately to severely active Crohn's disease with evidence of inflammation who have had an inadequate response to, or are unable to tolerate, conventional CD therapies and inhibitors of TNF-α.
Important Limitations: In CD, TYSABRI should not be used in combination with immunosuppressants or inhibitors of TNF-α. 1.1 Multiple Sclerosis (MS) TYSABRI is indicated as monotherapy for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
TYSABRI increases the risk of PML. When initiating and continuing treatment with TYSABRI, physicians should consider whether the expected benefit of TYSABRI is sufficient to offset this risk. 1.2 Crohn's Disease (CD) TYSABRI is indicated for inducing and maintaining clinical response and remission in adult patients with moderately to severely active Crohn's disease with evidence of inflammation who have had an inadequate response to, or are unable to tolerate, conventional CD therapies and inhibitors of TNF-α.
TYSABRI should not be used in combination with immunosuppressants (e.g., 6-mercaptopurine, azathioprine, cyclosporine, or methotrexate) or inhibitors of TNF-α.
TYSABRI increases your chance (risk) of getting a rare brain infection that usually leads to death or severe disability. This infection is called progressive multifocal leukoencephalopathy (PML). If PML happens, it usually happens in people with weakened immune systems. There is no known treatment, prevention, or cure for PML.
Your chance of getting PML may be higher if you are also being treated with other medicines that can weaken your immune system, including other treatments for Multiple Sclerosis (MS) and Crohn's disease (CD). You should not take certain medicines that weaken your immune system at the same time you are taking TYSABRI. Even if you use TYSABRI alone to treat your MS or CD, you can still get PML.
Your risk of getting PML is higher if you: have been infected by the John Cunningham Virus (JCV). JCV is a common virus that is harmless in most people but can cause PML in people who have weakened immune systems, such as people taking TYSABRI. Most people who are infected by JCV do not know it or do not have any symptoms.
This infection usually happens in childhood. Before you start receiving TYSABRI or during your treatment, your doctor may do a blood test to check if you have been infected by JCV. have received TYSABRI for a long time, especially longer than 2 years have received certain medicines that can weaken your immune system before you start receiving TYSABRI Your risk of getting PML is greatest if you have all 3 risk factors listed above.
There may be other risk factors for getting PML during TYSABRI treatment that we do not know about yet. Your doctor should discuss the risks and benefits of TYSABRI treatment with you before you decide to receive TYSABRI. See “
” While you receive TYSABRI, and for 6 months after you stop receiving TYSABRI, it is important that you call your doctor right away if you have any new or worsening medical problems that have lasted several days. These may be new or sudden and include problems with: thinking balance eyesight weakness on 1 side of your body strength using your arms and legs Tell all your doctors that you are receiving TYSABRI.
Because of your risk of getting PML while you receive TYSABRI, TYSABRI is available only through a restricted distribution program called the TOUCH ® Prescribing Program. To receive TYSABRI, you must talk to your doctor and understand the risks and benefits of TYSABRI and agree to follow all of the instructions in the TOUCH ® Prescribing Program.
TYSABRI is only: prescribed by doctors who are enrolled in the TOUCH ® Prescribing Program given by an infusion nurse from an infusion center that is enrolled in the TOUCH ® Prescribing Program given to people who are enrolled in the TOUCH ® Prescribing Program Before you receive TYSABRI, your doctor will: explain the TOUCH ® Prescribing Program to you have you sign the TOUCH ® Patient Enrollment Form What is TYSABRI?
TYSABRI is a prescription medicine used to treat adults with: relapsing forms of Multiple Sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease. TYSABRI increases the risk of PML. When starting and continuing treatment with TYSABRI, it is important that you discuss with your doctor whether the expected benefit of TYSABRI is enough to outweigh this risk.
moderate to severe Crohn's disease (CD). TYSABRI is used: to reduce signs and symptoms of CD in people who have not been helped enough by, or cannot use the usual CD medicines and medicines called tumor necrosis factor (TNF) inhibitors. It is not known if TYSABRI is safe and effective in children under 18 years of age. Who should not receive TYSABRI?
Do not receive TYSABRI if you: have PML are allergic to natalizumab or any of the ingredients in TYSABRI. See the end of this Medication Guide for a complete list of ingredients in TYSABRI. Talk to your doctor before receiving TYSABRI if you have any of these conditions.
Before you receive TYSABRI, tell your doctor if you: have medical conditions that can weaken your immune system, including: HIV infection or AIDS leukemia or lymphoma an organ transplant other medical conditions that can weaken your immune system have any new or worsening medical problems that have lasted several days. These may be new or sudden and include problems with: thinking strength eyesight weakness on 1 side of your body balance using your arms and legs have had hives, itching or trouble breathing during or after receiving a dose of TYSABRI have a fever or infection (including shingles or any unusually long lasting infection) are pregnant or plan to become pregnant.
TYSABRI may cause low platelets (thrombocytopenia) and low red blood cells (anemia) in your newborn baby if you take TYSABRI while you are pregnant. It is not known if TYSABRI can cause birth defects. are breastfeeding or plan to breastfeed. TYSABRI can pass into your breast milk. It is not known if the TYSABRI that passes into your breast milk can harm your baby.
Talk to your doctor about the best way to feed your baby while you receive TYSABRI. Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins and herbal supplements. Especially tell your doctor if you take medicines that can weaken your immune system. Ask your doctor if you are not sure.
Know the medicines you take. Keep a list of them to show your doctor and pharmacist when you get a new medicine. How should I receive TYSABRI? TYSABRI is given 1 time every 4 weeks through a needle placed in your vein (IV infusion). Each infusion will last about 1 hour. Before each TYSABRI dose you will be asked questions to make sure TYSABRI is still right for you.
What are the possible side effects of TYSABRI? TYSABRI may cause serious side effects, including: Herpes Infections. TYSABRI may increase your risk of getting an infection of the brain or the covering of your brain and spinal cord (encephalitis or meningitis) caused by herpes viruses that may lead to death. Call your doctor right away if you have sudden fever, severe headache, or if you feel confused after receiving TYSABRI.
Herpes infections of the eye, causing blindness in some patients, have also occurred. Call your doctor right away if you have changes in vision, eye redness, or eye pain. Liver damage. Symptoms of liver damage can include: yellowing of the skin and eyes (jaundice) unusual darkening of the urine nausea feeling tired or weak vomiting Call your doctor right away if you have symptoms of liver damage.
Your doctor can do blood tests to check for liver damage. Allergic reactions, including serious allergic reactions. Symptoms of an allergic reaction can include: hives dizziness nausea itching wheezing flushing of skin trouble breathing chills low blood pressure chest pain rash Serious allergic reactions usually happen within 2 hours of the start of your infusion, but they can happen at any time after you receive TYSABRI.
Tell your doctor right away if you have any symptom of an allergic reaction, even if it happens after your infusion. You may need treatment if you are having an allergic reaction. Infections. TYSABRI may increase your chance of getting an unusual or serious infection because TYSABRI can weaken your immune system. You have a higher risk of getting infections if you also take other medicines that can weaken your immune system.
Low platelet counts. TYSABRI may cause the number of platelets in your blood to be reduced. Call your healthcare provider if you have any of the following symptoms: easy bruising heavier menstrual periods than are normal bleeding from your gums or nose that is new or takes longer than usual to stop bleeding from a cut that is hard to stop small scattered red spots on your skin that are red, pink, or purple The most common side effects of TYSABRI include: headache lung i
sofidex [Internet]. Daloreum; c2026. Natalizumab; [reviewed 2026 Aug 2; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/natalizumab
sofidex. (2026, August 2). Natalizumab. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/natalizumab
Natalizumab. sofidex. Reviewed August 2, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/natalizumab
The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.